Brief: Alphamab Oncology Says IND Application For JSKN027 Accepted By CDE, NMPA China
17/12/2025 10:06
Dec 17 (Reuters) - Alphamab Oncology 9966.HK: IND APPLICATION FOR JSKN027 ACCEPTED BY CDE JSKN027 ACCEPTED BY CENTER FOR DRUG EVALUATION BY NMPA CHINA Further company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)